A Chinese medicine monomer drug combination preparation for treating neurotransmitter imbalance and its application

Abstract

The present invention provides a Chinese medicine monomer drug combination preparation for treating neurotransmitter imbalance and its application, belonging to the field of medical technology. The combination preparation is composed of ferulic acid and verbascoside, wherein the mass ratio of ferulic acid to verbascoside is 1:9, 1:1 or 9:1, preferably 2.5μM ferulic acid and 22.5μM verbascoside. Studies have found that the combination preparation can significantly reduce the abnormal increase in glutamate (Glu) secretion, increase the abnormal decrease in γ-aminobutyric acid (GABA) secretion, and restore the balance of excitatory and inhibitory neurotransmitters. Through synergistic effects, the combination preparation achieves better efficacy and reduces side effects while reducing the dosage of the drug. Compared with traditional treatment methods, the present invention has the advantages of a clear mechanism of action and controllable quality, and has a wide range of clinical application prospects.

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and in particular relates to a Chinese medicine monomer drug combination preparation for treating neurotransmitter imbalance and an application thereof. Background Art

[0002] Existing studies have shown that the imbalance of excitatory and inhibitory neurotransmitters may be involved in the pathological process of neurological diseases such as insomnia, anxiety, depression, mania, Parkinson's disease, etc., which are characterized by increased glutamate (Glu) concentration and decreased γ-aminobutyric acid (GABA) concentration. Stress is an important risk factor for neurotransmitter imbalance, which can induce neuronal dysfunction and damage nerve cell vitality, thereby aggravating the dysfunction of the nervous system. Therefore, restoring the balance of excitatory and inhibitory neurotransmitters can improve nerve cell vitality and function, and effectively improve the function of the nervous system.

[0003] Traditional Chinese medicine believes that the causes of depression include emotional disorders, organ dysfunction, and insufficient qi and blood. Through syndrome differentiation and treatment, different prescriptions can be used for treatment, which can play a role in overall regulation and balance of yin and yang, reduce the side effects of Western medicine, and significantly improve the quality of life of patients, which has significant advantages. The prescription and compatibility of Chinese medicine prescriptions are usually composed of two or more Chinese medicines, and each Chinese medicine contains a variety of monomer compound components, including active, inactive and toxic components, with unpredictable dose-response and toxicological properties, so there are potential problems of complex components and unclear mechanisms. Therefore, it is crucial to clarify the composition and content of the material basis components of Chinese medicine prescriptions. On this basis, the combination of Chinese medicine monomer drugs formed in proportion has the advantages of clear mechanism and controllable quality.

[0004] The inventors previously analyzed the chemical composition of the Baihe Dihuang Tang benchmark sample through fingerprints and multivariate statistics, and determined that dioscin, ferulic acid, verbascoside, and catalpol were its key quality markers. Among them, ferulic acid has antioxidant, antibacterial, and antiviral effects, and verbascoside has antioxidant, neuroprotective, and immune-regulating effects. However, there is no literature report on the role of the Chinese medicine monomer drug combination of ferulic acid and verbascoside in restoring the imbalance of excitatory / inhibitory transmitters in nerve cells. Summary of the invention

[0005] The object of the present invention is to provide a Chinese medicine monomer pharmaceutical composition for treating diseases related to neurotransmitter imbalance by correcting the imbalance of excitatory and inhibitory neurotransmitters in nerve cells: ferulic acid and verbascoside, so as to apply the composition to the development of new drugs for improving nerve function.

[0006] To achieve the above object, the present invention provides the following technical solutions:

[0007] In a first aspect, the present invention provides a Chinese medicine monomer drug combination preparation for treating excitatory neurotransmitter imbalance and inhibitory neurotransmitter imbalance, wherein the Chinese medicine monomer drug combination preparation consists of ferulic acid and verbascoside;

[0008] In the Chinese medicine monomer drug combination preparation, the mass ratio of the ferulic acid to the verbascoside is 1:9, 1:1 or 9:1.

[0009] Preferably, the Chinese medicine monomer drug combination preparation consists of 2.5 μM ferulic acid and 22.5 μM verbascoside.

[0010] Preferably, the imbalance of excitatory neurotransmitters refers to abnormal increase in glutamate secretion from nerve cells;

[0011] The inhibitory neurotransmitter imbalance refers to an abnormal decrease in the secretion of γ-aminobutyric acid in nerve cells.

[0012] In a second aspect, the present invention provides a use of a Chinese medicine monomer composition in the preparation of a therapeutic drug for a neurological disease caused by an imbalance of neurotransmitters, wherein the neurological disease caused by an imbalance of neurotransmitters is insomnia, anxiety, depression, mania and Parkinson's disease;

[0013] The traditional Chinese medicine monomer drug composition consists of ferulic acid and verbascoside.

[0014] Preferably, the Chinese medicine monomer pharmaceutical composition consists of 2.5 μM ferulic acid and 22.5 μM verbascoside.

[0015] In a third aspect, the present invention provides an application of a Chinese herbal medicine monomer composition in the preparation of a pharmaceutical preparation for restoring decreased nerve cell activity, wherein the Chinese herbal medicine monomer composition consists of 2.5 μM ferulic acid and 22.5 μM verbascoside.

[0016] In a fourth aspect, the present invention provides an application of a Chinese herbal monomer pharmaceutical composition in the preparation of a pharmaceutical preparation for restoring an imbalance of excitatory neurotransmitters, wherein the Chinese herbal monomer pharmaceutical composition consists of 2.5 μM ferulic acid and 22.5 μM verbascoside.

[0017] Preferably, the imbalance of excitatory neurotransmitters refers to abnormal increase in glutamate secretion from nerve cells caused by corticosterone.

[0018] Preferably, the abnormally increased glutamate secretion of nerve cells means that the glutamate secreted by nerve cells is higher than that of normal nerve cells.

[0019] In a fifth aspect, the present invention provides an application of a Chinese herbal monomer pharmaceutical composition in the preparation of a pharmaceutical preparation for restoring inhibitory neurotransmitter imbalance caused by corticosterone, wherein the Chinese herbal monomer pharmaceutical composition consists of 2.5 μM ferulic acid and 22.5 μM verbascoside.

[0020] Preferably, the inhibitory neurotransmitter imbalance refers to an abnormal decrease in the secretion of γ-aminobutyric acid in nerve cells caused by corticosterone.

[0021] Preferably, the abnormally reduced secretion of γ-aminobutyric acid by nerve cells means that the γ-aminobutyric acid secreted by nerve cells is lower than that of normal nerve cells.

[0022] The beneficial effects of the present invention are:

[0023] The invention provides a Chinese medicine monomer drug combination preparation composed of ferulic acid and verbascoside, which is used to treat excitatory neurotransmitter imbalance and inhibitory neurotransmitter imbalance. Ferulic acid and verbascoside show significant synergistic effect at a specific ratio (2.5 μM ferulic acid and 22.5 μM verbascoside). The combination can simultaneously reduce the abnormal increase of the excitatory neurotransmitter glutamate (Glu), and increase the abnormal decrease of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), thereby restoring the balance of neurotransmitters.

[0024] At the same time, experimental results showed that the combined preparation could significantly improve the decrease in neuronal cell activity induced by corticosterone (CORT) and increase cell survival rate.

[0025] Secondly, by combining in a specific ratio, better curative effect is achieved while reducing the concentration of ferulic acid and verbascoside, reducing the potential side effects of the drug and improving the safety of medication. Moreover, the present invention adopts a clear monomer component and a specific ratio combination, has a clear mechanism of action, is conducive to standardized production and quality control, and solves the problem of complex ingredients and unpredictable dosage response of traditional Chinese medicine.

[0026] In summary, the Chinese medicine monomer drug combination preparation of the present invention restores the balance of the nervous system by synergistically regulating excitatory and inhibitory neurotransmitters, has significant therapeutic effect and safety, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The effect of ferulic acid FA on the survival rate of nerve cells;

[0028] Figure 2 The effect of verbascoside ACT on the survival rate of nerve cells;

[0029] Figure 3 The effect of ferulic acid on the survival rate of the neurotransmitter imbalance cell model;

[0030] Figure 4 The effect of verbascoside on the survival rate of the neurotransmitter imbalance cell model;

[0031] Figure 5To study the effect of combined application of ferulic acid FA and verbascoside ACT on the cell state of the neurotransmitter imbalance cell model;

[0032] Figure 6 To study the effect of combined application of ferulic acid FA and verbascoside ACT on cell survival rate in a neurotransmitter imbalance cell model;

[0033] Figure 7 To investigate the effects of ferulic acid and verbascoside combined on the secretion of γ-aminobutyric acid in a cell model of neurotransmitter imbalance.

[0034] Figure 8 To investigate the effects of combined application of ferulic acid and verbascoside on glutamate secretion in a cell model of neurotransmitter imbalance. DETAILED DESCRIPTION

[0035] The examples are provided to better illustrate the present invention, but the present invention is not limited to the examples. Therefore, those skilled in the art may make non-essential improvements and adjustments to the implementation scheme according to the above invention content, which still fall within the protection scope of the present invention.

[0036] Example 1

[0037] Effects of Ferulic Acid on Survival Rate of Neuronal Cells

[0038] 1. Take Neuro-2a cells in the logarithmic growth phase, digest them with trypsin to obtain a cell suspension, and then add 1×10 4 100 μL of cells were seeded into each well of a 96-well plate and incubated at 37°C with 5% CO 2 After culturing in a cell culture incubator for 24 h, the supernatant was discarded.

[0039] 2. Add 100 μL DMEM-F12 complete medium to the control group, add DMEM-F12 complete medium containing 200 μM, 400 μM, 600 μM, 800 μM, and 1000 μM ferulic acid (FA) to each experimental group, and set up a blank control group without cells and only with complete medium. Set up 5 replicate wells for each group.

[0040] 3. After continuing to culture for 24 hours, discard the supernatant, add 100 μL of DMEM-F12 complete medium to each well, add 10 μL of CCK8 solution to each well, incubate in a 37°C incubator for 2 hours, detect the absorbance at 450nm, and calculate the cell viability.

[0041] 4. After continuing to culture for 24 hours, discard the supernatant, add 100 μL of DMEM-F12 complete medium to each well, add 10 μL of CCK8 solution to each well, incubate in a 37°C incubator for 2 hours, detect the absorbance at 450nm, and calculate the cell viability.

[0042] Example 2

[0043] Effects of Verbascoside on Survival Rate of Neuronal Cells

[0044] 1. Take Neuro-2a cells in the logarithmic growth phase, digest them with trypsin to obtain a cell suspension, and then add 1×10 4 100 μL of cells were seeded into each well of a 96-well plate and incubated at 37°C with 5% CO 2 After culturing in a cell culture incubator for 24 h, the supernatant was discarded.

[0045] 2. Add 100 μL DMEM-F12 complete medium to the control group, add DMEM-F12 complete medium containing 100 μM, 200 μM, 400 μM, 600 μM, and 800 μM of verbascoside (ACT) to each experimental group, and set up a blank control group without cells and only with complete medium. Set up 5 replicate wells for each group.

[0046] 3. After continuing to culture for 24 hours, discard the supernatant, add 100 μL of DMEM-F12 complete medium to each well, add 10 μL of CCK8 solution to each well, incubate in a 37°C incubator for 2 hours, detect the absorbance at 450nm, and calculate the cell viability.

[0047] Example 3

[0048] Effects of Ferulic Acid on the Survival Rate of Cell Models with Neurotransmitter Imbalance

[0049] 1. Take Neuro-2a cells in the logarithmic growth phase, digest them with trypsin to obtain a cell suspension, and then add 1×10 4 100 μL of cells were seeded into each well of a 96-well plate and incubated at 37°C with 5% CO 2 After culturing in a cell culture incubator for 24 h, the supernatant was discarded.

[0050] 2. Add 100 μL DMEM-F12 complete medium to the control group, add 100 μL DMEM-F12 complete medium containing CORT 600 μM to the experimental group 2, add DMEM-F12 complete medium containing CORT 600 μM and FA 25 μM, 50 μM, 100 μM, and 200 μM to the experimental groups 3-6, and set up a blank control group without cells but with complete medium. Set up 5 replicate wells for each group.

[0051] 3. After continuing to culture for 24 hours, discard the supernatant, add 100 μL of DMEM-F12 complete medium to each well, add 10 μL of CCK8 solution to each well, incubate in a 37°C incubator for 2 hours, detect the absorbance at 450nm, and calculate the cell viability.

[0052] Example 4

[0053] Effects of Verbascoside on the Survival Rate of Neurotransmitter Imbalance Cell Model

[0054] 1. Take Neuro-2a cells in the logarithmic growth phase, digest them with trypsin to obtain a cell suspension, and then add 1×10 4 100 μL of cells were seeded into each well of a 96-well plate and incubated at 37°C with 5% CO 2 After culturing in a cell culture incubator for 24 h, the supernatant was discarded.

[0055] 2. The control group was added with 100 μL DMEM-F12 complete medium, the experimental group 2 was added with 100 μL DMEM-F12 complete medium containing CORT 600 μM, and the experimental groups 3-6 were added with DMEM-F12 complete medium containing CORT 600 μM and ACT 100 μM, 50 μM, 25 μM, and 12.5 μM. At the same time, a blank control group without cells and only with complete medium was set up, and 5 replicates were set up for each group.

[0056] 3. After continuing to culture for 24 hours, discard the supernatant, add 100 μL of DMEM-F12 complete medium to each well, add 10 μL of CCK8 solution to each well, incubate in a 37°C incubator for 2 hours, detect the absorbance at 450nm, and calculate the cell viability.

[0057] Example 5

[0058] Effects of combined application of ferulic acid and verbascoside on the cell state of a cell model of neurotransmitter imbalance

[0059] 1. Take Neuro-2a cells in the logarithmic growth phase, digest them with trypsin to obtain a cell suspension, and plate 1×10 6 Cells were seeded in 6-well plates and incubated at 37°C with 5% CO 2 After culturing in a cell culture incubator for 24 h, the supernatant was discarded.

[0060] 2. The control group was added with DMEM-F12 complete medium, the experimental group 1 was added with DMEM-F12 complete medium containing CORT 600μM, the experimental group 2 was added with DMEM-F12 complete medium containing CORT 600μM and FA 50μM, the experimental group 3 was added with DMEM-F12 complete medium containing CORT 600μM and ACT 25μM, the experimental group 4 was added with DMEM-F12 complete medium containing CORT 600μM, FA 22.5μM and ACT2.5μM, the experimental group 5 was added with DMEM-F12 complete medium containing CORT 600μM, FA 12.5μM and ACT 12.5μM, the experimental group 6 was added with DMEM-F12 complete medium containing CORT 600μM, FA 2.5μM and ACT 22.5μM, the experimental group 7 was added with DMEM-F12 complete medium containing CORT 600μM and RU486 2.5 μM DMEM-F12 complete medium, treated for 24 h, 3 replicate wells per group.

[0061] 3. After the treatment, observe the changes in the cells under a microscope.

[0062] Example 6

[0063] Effect of combined application of ferulic acid and verbascoside on the survival rate of a cell model with neurotransmitter imbalance

[0064] 1. Take Neuro-2a cells in the logarithmic growth phase, digest them with trypsin to obtain a cell suspension, and plate 1×10 4 Cells were seeded in 96-well plates and incubated at 37°C with 5% CO 2 After culturing in a cell culture incubator for 24 h, the supernatant was discarded.

[0065] 2. The control group was added with DMEM-F12 complete medium, the experimental group 1 was added with DMEM-F12 complete medium containing CORT 600μM, the experimental group 2 was added with DMEM-F12 complete medium containing CORT 600μM and FA 50μM, the experimental group 3 was added with DMEM-F12 complete medium containing CORT 600μM and ACT 25μM, the experimental group 4 was added with DMEM-F12 complete medium containing CORT 600μM, FA 22.5μM and ACT2.5μM, the experimental group 5 was added with DMEM-F12 complete medium containing CORT 600μM, FA 12.5μM and ACT 12.5μM, the experimental group 6 was added with DMEM-F12 complete medium containing CORT 600μM, FA 2.5μM and ACT 22.5μM, the experimental group 7 was added with DMEM-F12 complete medium containing CORT 600μM and RU486 2.5 μM DMEM-F12 complete medium, 5 replicate wells per group.

[0066] 3. After continuing to culture for 24 hours, discard the supernatant, add 100 μL of DMEM-F12 complete medium to each well, add 10 μL of CCK8 solution to each well, incubate in a 37°C incubator for 2 hours, detect the absorbance at 450nm, and calculate the cell viability.

[0067] Example 7

[0068] Effects of combined application of ferulic acid and verbascoside on GABA content in a cell model of neurotransmitter imbalance

[0069] 1. Take Neuro-2a cells in the logarithmic growth phase, digest them with trypsin to obtain a cell suspension, and plate 1×10 4 Cells were seeded in 96-well plates and incubated at 37°C with 5% CO 2 After culturing in a cell culture incubator for 24 h, the supernatant was discarded.

[0070] 2. The control group was added with DMEM-F12 complete medium, the experimental group 1 was added with DMEM-F12 complete medium containing CORT 600μM, the experimental group 2 was added with DMEM-F12 complete medium containing CORT 600μM and FA 50μM, the experimental group 3 was added with DMEM-F12 complete medium containing CORT 600μM and ACT 25μM, the experimental group 4 was added with DMEM-F12 complete medium containing CORT 600μM, FA 22.5μM and ACT2.5μM, the experimental group 5 was added with DMEM-F12 complete medium containing CORT 600μM, FA 12.5μM and ACT 12.5μM, the experimental group 6 was added with DMEM-F12 complete medium containing CORT 600μM, FA 2.5μM and ACT 22.5μM, the experimental group 7 was added with DMEM-F12 complete medium containing CORT 600μM and RU486 2.5 μM DMEM-F12 complete medium, 5 replicate wells per group.

[0071] 3. After continuing to culture for 24 hours, collect the supernatant and detect the content of neurotransmitter GABA. Add 10μl of supernatant and 40μl of sample diluent to each well and mix them, incubate at 37℃ for 30min. Add 250μl of washing solution to the well and wash the plate 5 times. Add 50μl of enzyme labeling reagent, incubate at 37℃ for 30min and wash 5 times. Add 50μl of color developer A and B to each well, incubate at 37℃ for 10min, then add 50μl of stop solution, measure the absorbance at 450nm with an enzyme labeler, and calculate the sample concentration based on the OD value.

[0072] Example 8

[0073] Effect of combined application of ferulic acid and verbascoside on Glu content in a neurotransmitter imbalance cell model 1. Neuro-2a cells in logarithmic growth phase were obtained, and cell suspension was obtained after trypsin digestion. 1×10 4 Cells were seeded in 96-well plates and incubated at 37°C with 5% CO 2 After culturing in a cell culture incubator for 24 h, the supernatant was discarded.

[0074] 2. The control group was added with DMEM-F12 complete medium, the experimental group 1 was added with DMEM-F12 complete medium containing CORT 600μM, the experimental group 2 was added with DMEM-F12 complete medium containing CORT 600μM and FA 50μM, the experimental group 3 was added with DMEM-F12 complete medium containing CORT 600μM and ACT 25μM, the experimental group 4 was added with DMEM-F12 complete medium containing CORT 600μM, FA 22.5μM and ACT2.5μM, the experimental group 5 was added with DMEM-F12 complete medium containing CORT 600μM, FA 12.5μM and ACT 12.5μM, the experimental group 6 was added with DMEM-F12 complete medium containing CORT 600μM, FA 2.5μM and ACT 22.5μM, the experimental group 7 was added with DMEM-F12 complete medium containing CORT 600μM and RU486 2.5 μM DMEM-F12 complete medium, 5 replicate wells per group.

[0075] 3. After continuing to culture for 24 hours, collect the supernatant and detect the content of neurotransmitter Glu. Add 10μl of supernatant and 40μl of sample diluent to each well and mix them, incubate at 37℃ for 30 minutes. Add 250μl of washing solution to the well and wash the plate 5 times. Add 50μl of enzyme labeling reagent, incubate at 37℃ for 30 minutes and then wash 5 times. Add 50μl of color developer A and B to each well, incubate at 37℃ for 10 minutes, then add 50μl of stop solution, measure the absorbance at 450nm with an enzyme labeler, and calculate the sample concentration based on the OD value.

[0076] Experimental results:

[0077] The results obtained in Example 1 are as follows Figure 1 As shown, it can be seen from the results that FA concentrations within 200 μM have no cytotoxicity to Neuro-2a, while concentrations above 400 μM can significantly reduce cell survival rate. Therefore, the present invention selects FA concentrations within 200 μM for experiments.

[0078] The results obtained in Example 2 are as follows Figure 2 As shown in the results, it can be seen that ACT concentrations below 100 μM have no cytotoxicity to Neuro-2a, while concentrations above 200 μM can significantly reduce cell survival rate.

[0079] The results obtained in Example 3 are as follows Figure 3 As shown in the results, it can be seen that the concentrations of FA in the range of 25-200μM can significantly improve the survival rate of CORT-induced model cells, among which the cell survival rate of the FA 50μM group was the highest, and the P value was <0.01, and the difference was statistically significant.

[0080] The results obtained in Example 4 are as follows Figure 4 As shown in the results, it can be seen that the concentrations of ACT in the range of 12.5-50μM can significantly increase the survival rate of CORT-induced model cells, among which the cell survival rate of the FA 25μM group was the highest, and the P value was <0.01, and the difference was statistically significant.

[0081] The results obtained in Example 5 are as follows Figure 5 As shown in the results, it can be seen that compared with the control group, the cell number and density of the experimental group 1 decreased significantly; compared with the experimental group 1, the cell number and density of the FA+TAC (2.5μM+22.5μM) group increased significantly, and were better than the FA 50μM group, TAC 25μM group, FA+TAC (12.5μM+12.5μM) group and FA+TAC (22.5μM+2.5μM) group.

[0082] The results obtained in Example 6 are as follows Figure 6 As shown in the results, it can be seen that compared with the control group, the cell activity of experimental group 1 was significantly decreased, and the P value was <0.01, and the difference was statistically significant, indicating that CORT treatment would lead to a decrease in the activity of Neuro-2a cells, and the FA+TAC (2.5μM+22.5μM) group (experimental group 7) could significantly increase the cell viability of experimental group 1, and the effect was better than that of the FA50μM group, TAC 25μM group, FA+TAC (12.5μM+12.5μM) group and FA+TAC (22.5μM+2.5μM) group; the cell viability of the FA+TAC (12.5μM+12.5μM) group and the FA+TAC (22.5μM+2.5μM) group was better than that of the FA 50μM group and TAC 25μM group, indicating that the combined use of FA+TAC has a significant synergistic relationship and can significantly improve cell viability, while the FA+TAC (1:9) group has the best efficacy, which is better than the FA+TAC (5:5) group or the FA+TAC (9:1) group, with unexpected technical effects.

[0083] The results obtained in Example 7 are as follows Figure 7As shown in the results, it can be seen that the GABA content in experimental group 1 was significantly reduced compared with the control group, with a P value of <0.01, and the difference was statistically significant, indicating that CORT treatment would lead to a decrease in cellular GABA secretion; the FA+TAC (2.5μM+22.5μM) group (experimental group 7) could significantly increase the GABA content of the model cells, with a P value of <0.01, and the difference was statistically significant, and the content was higher than that of the FA50μM group, TAC 25μM group, FA+TAC (12.5μM+12.5μM) group, FA+TAC (22.5μM+2.5μM) group, and the positive control drug RU486 group.

[0084] Therefore, we can conclude that CORT treatment leads to a significant decrease in intracellular GABA content, inducing an imbalance in inhibitory neurotransmitters, while FA and TAC show a synergistic effect at a specific ratio (2.5μM+22.5μM), significantly increasing the GABA content. This may be due to the fact that the two substances work together on different pathways or targets to enhance the synthesis or release of inhibitory neurotransmitters.

[0085] The results obtained in Example 8 are as follows Figure 8 As shown in the results, it can be seen that the Glu content in the experimental group 1 was significantly increased compared with the control group, with a P value of <0.01, and the difference was statistically significant, indicating that CORT treatment would lead to increased cellular Glu secretion, and the FA+TAC (2.5μM+22.5μM) group could significantly reduce the Glu content of the model cells, and the content was lower than that in the FA50μM group, TAC 25μM group, FA+TAC (12.5μM+12.5μM) group and FA+TAC (22.5μM+2.5μM) group.

[0086] Therefore, we can conclude that CORT treatment leads to an increase in Glu content, indicating that CORT can induce an imbalance of excitatory neurotransmitters and cause neurological diseases, while the specific combination of FA and TAC (2.5μM+22.5μM) can effectively reduce the Glu level and achieve a better effect of reducing the Glu level by reducing the concentrations of FA and TAC.

[0087] In general, the present invention reveals that FA and TAC can synergistically regulate the neurotransmitter imbalance caused by CORT at a specific ratio, thereby providing a new treatment method for effectively treating neurological diseases caused by neurotransmitter imbalance.

Claims

1. A Chinese medicine monomer drug combination preparation for treating depression caused by imbalance of excitatory neurotransmitters and inhibitory neurotransmitters, characterized in that: The Chinese medicine monomer drug combination preparation is composed of 2.5 μM ferulic acid and 22.5 μM verbascoside; The excitatory neurotransmitter imbalance refers to the abnormal increase in glutamate secretion from nerve cells caused by corticosterone; The inhibitory neurotransmitter imbalance refers to the abnormal decrease in the secretion of γ-aminobutyric acid in nerve cells caused by corticosterone.

2. Use of a Chinese medicine monomer composition in the preparation of a therapeutic drug for depression caused by an imbalance of excitatory neurotransmitters and an imbalance of inhibitory neurotransmitters, characterized in that: The Chinese medicine monomer pharmaceutical composition is composed of 2.5 μM ferulic acid and 22.5 μM verbascoside; The excitatory neurotransmitter imbalance refers to the abnormal increase in glutamate secretion from nerve cells caused by corticosterone; The inhibitory neurotransmitter imbalance refers to the abnormal decrease in the secretion of γ-aminobutyric acid in nerve cells caused by corticosterone.

Images